Back to search results

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

IsraelRecruitingPHASE2

Conditions

Aortic Stenosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Heart Center Research Llc, Huntsville, Alabama, United States

    Contact: Study coordinator (Amy Williams) · awilliams@theheartcenter.md · +1 256 519 8255
    Contact: Principal Investigator (Vernon R Hunter)

  • Cardiovascular Res Found, Beverly Hills, California, United States

    Contact: Study coordinator (Juan Ramos) · juan.ramos@cvmg.com · +1 310 278 3400
    Contact: Principal Investigator (Ronald P Karlsberg)

  • National Heart Institute, Beverly Hills, California, United States

    Contact: Study coordinator (Maria Flores) · mflores@nationalheartinstitute.org · +1 301 289 5221
    Contact: Principal Investigator (Norman Lepor)

  • Flourish Clinical Resrch Covin, Covina, California, United States

    Contact: Study coordinator (Sarita Garcia) · sgarcia@flourishresearch.com · +1 714 299 2412
    Contact: Principal Investigator (Fahed Bitar)

  • Valley Clinical Trials, Northridge, California, United States

    Contact: Study coordinator (Haydee Gutierrez) · haydee@valleyclinicaltrials.com · +1 818 280 4220
    Contact: Principal Investigator (Mehrdad Ariani)

  • Stanford University Medical Center, Palo Alto, California, United States

    Contact: Study coordinator (Tamara Bazouzi) · bazouzit@stanford.edu · +1 650 736 7878
    Contact: Principal Investigator (Abha Khandelwal)

  • University Of California San Diego, San Diego, California, United States

    Contact: Study coordinator (Ruby Swaim) · rswaim@health.ucsd.edu · +1 858 246 2510
    Contact: Principal Investigator (Anna Narezkina)

  • UC San Francisco Medical Center, San Francisco, California, United States

    Contact: Study coordinator (Liliann Zou) · liliann.zou@ucsf.edu · +1 415 514 3156
    Contact: Principal Investigator (Eveline Stock)

  • Excel Medical Clinical Trials LLC, Boca Raton, Florida, United States

  • Nova Clinical Research LLC, Bradenton, Florida, United States

    Contact: Study coordinator (Sade Andrews) · sade.andrews@novaclinicalresearch.com · +1 941 792 6564
    Contact: Principal Investigator (Christian Zellner)

  • Flourish Res Acq LLC North Miami, Miami, Florida, United States

    Contact: Study coordinator (Ashlee Sealy) · asealy@flourishresearch.com
    Contact: Principal Investigator (Rimsky Denis.)

  • Inpatient Research Clinical LLC, Miami Lakes, Florida, United States

    Contact: Study coordinator (Dora Gutierrez) · dgutierrez@inpatientresearch.com · +1 786 502 4303
    Contact: Principal Investigator (Alexis Gutierrez.)

  • Advanced Research for Health Improvement LLC, Naples, Florida, United States

  • Midwest Heart and Vascular Spec, Overland Park, Kansas, United States

    Contact: Study coordinator (Elizabeth Fulks) · Elizabeth.fulks@hcahealthcare.com · +1 913 253 3000
    Contact: Principal Investigator (Vasvi Singh.)

  • Tufts Medical Center, Boston, Massachusetts, United States

    Contact: Study coordinator (Juan Carlos Collado Falcon) · juan.carlos.collado.falcon@tuftsmedicine.org · +1 617 636 5897
    Contact: Principal Investigator (Benjamin Wessler)

  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Victoria Viscosi) · vviscosi@mgh.harvard.edu · +1 813 943 3440
    Contact: Principal Investigator (Michael Honigberg)

  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Victoria Viscosi) · vviscosi@mgh.harvard.edu
    Contact: Principal Investigator (Michael Honigberg)

  • Brigham and Womens Hosp Harvard Med School, Boston, Massachusetts, United States

    Contact: Study coordinator (Sam Wong) · swong1@bwh.harvard.edu · +1 617 347 8680
    Contact: Principal Investigator (Rhanderson Cardoso)

  • Brigham and Womens Hosp Harvard Med School, Boston, Massachusetts, United States

    Contact: Study coordinator (Sam Wong) · swong1@bwh.harvard.edu · +1 617 525 1227
    Contact: Principal Investigator (Rhanderson Cardoso)

  • Henry Ford Hospital, Detroit, Michigan, United States

    Contact: Study coordinator (Jodi Carter, BS, CCRP) · +1 (313) 916-3613
    Contact: Principal Investigator (Khaled Abdul-Nour)

  • Henry Ford Hospital, Detroit, Michigan, United States

    Contact: Study coordinator (Jodi Carter) · jcarte23@hfhs.org · +1 313 590 2407
    Contact: Principal Investigator (Khaled Abdul-Nour)

  • AA Medical Research Center, Flint, Michigan, United States

    Contact: Study coordinator (Fayyaz Shah) · fshah@aamrc.net · +1 810 237 1125
    Contact: Principal Investigator (Ahmed A Arif.)

  • William Beaumont Hospital, Royal Oak, Michigan, United States

    Contact: Study coordinator (Rachel Wylie) · rachel.wylie@corewellhealth.org · +1 248 551 4192
    Contact: Principal Investigator (Joel Skaistis)

  • Minneapolis Heart Institute, Minneapolis, Minnesota, United States

  • University Of Minnesota, Minneapolis, Minnesota, United States

    Contact: Study coordinator (Michelle Pitt) · henni032@umn.edu · +1 612 624 4948
    Contact: Principal Investigator (Daniel Duprez)

  • Overlook Medical Center, Summit, New Jersey, United States

    Contact: Study coordinator (Rosmery Montesino) · Rosmery.montesino@atlantichealth.org · +1 908 522 6279
    Contact: Principal Investigator (Robert Fishberg.)

  • Capital Cardiology Associates, Albany, New York, United States

    Contact: Study coordinator (Shreya Shah) · sshah@capitalcardiology.com
    Contact: Principal Investigator (Lance Sullenberger.)

  • New York Presbyterian Hospital, New York, New York, United States

  • Icahn School of Med at Mt Sinai, New York, New York, United States

    Contact: Study coordinator (Jay Krishna Katragadda) · jaykrishna.katragadda@mssm.edu · +1 212 659 9174
    Contact: Principal Investigator (Robert Rosenson.)

  • Strong Memorial Hospital, Rochester, New York, United States

    Contact: Study coordinator (Ferogh Shakouri) · ferogh_shakouri@URMC.Rochester.edu · +1 716 275 7753
    Contact: Principal Investigator (Robert Block)

  • Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States

    Contact: Study coordinator (Donna Davis) · donna.h.davis@advocatehealth.org
    Contact: Principal Investigator (Michael Shapiro)

  • Lindner Ctr At The Christ Hosp, Cincinnati, Ohio, United States

    Contact: Study coordinator (Meghan Grone) · Meghan.Grone@thechristhospital.com · +1 513 585 1777
    Contact: Principal Investigator (Sitaramesh Emani)

  • Ohio State University, Columbus, Ohio, United States

  • Perelman School of Medicine, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Manali Shah) · manali.shah2@pennmedicine.upenn.edu
    Contact: Principal Investigator (Archna Bajaj)

  • Orion Medical, Houston, Texas, United States

    Contact: Study coordinator (Lena Olivera Perez) · lena.oliveraperez@usheartandvascular.com
    Contact: Principal Investigator (Karan Bhalla)

  • Virginia Heart, Falls Church, Virginia, United States

    Contact: Study coordinator (Samira Kamali) · skamali@VirginiaHeart.com · +1 703 766 5920
    Contact: Principal Investigator (Tariq Haddad)

  • Carient Heart and Vascular, Manassas, Virginia, United States

    Contact: Study coordinator (Hameeda Tasneem) · htasneem@carient.com · +1 70 333 58 750
    Contact: Principal Investigator (Vikram Prasanna)

  • Novartis Investigative Site, Innsbruck, Tyrol, Austria

  • Novartis Investigative Site, Linz, Austria

  • Novartis Investigative Site, Vienna, Austria

  • Novartis Investigative Site, Vienna, Austria

  • Novartis Investigative Site, Vienna, Austria

  • Novartis Investigative Site, Genk, Limburg, Belgium

  • Novartis Investigative Site, Yvoir, Namur, Belgium

  • Novartis Investigative Site, Aalst, Oost Vlaanderen, Belgium

  • Novartis Investigative Site, Kortrijk, West-Vlaanderen, Belgium

  • Novartis Investigative Site, Roeselare, West-Vlaanderen, Belgium

  • Novartis Investigative Site, Cambridge, Ontario, Canada

  • Novartis Investigative Site, North York, Ontario, Canada

  • Novartis Investigative Site, Ottawa, Ontario, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Québec, Quebec, Canada

  • Novartis Investigative Site, Hradec Králové, Czechia

  • Novartis Investigative Site, Jaroměř, Czechia

  • Novartis Investigative Site, Prague, Czechia

  • Novartis Investigative Site, Prague, Czechia

  • Novartis Investigative Site, Prague, Czechia

  • Novartis Investigative Site, Esbjerg, Denmark

  • Novartis Investigative Site, Hvidovre, Denmark

  • Novartis Investigative Site, Roskilde, Denmark

  • Novartis Investigative Site, Viborg, Denmark

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Pessac, France

  • Novartis Investigative Site, Poitiers, France

  • Novartis Investigative Site, Rennes, France

  • Novartis Investigative Site, Frankfurt am Main, Hesse, Germany

  • Novartis Investigative Site, Kaiserslautern, Rhineland-Palatinate, Germany

  • Novartis Investigative Site, Dresden, Saxony, Germany

  • Novartis Investigative Site, Leipzig, Saxony, Germany

  • Novartis Investigative Site, Ahaus, Germany

  • Novartis Investigative Site, Berlin, Germany

  • Novartis Investigative Site, Bonn, Germany

  • Novartis Investigative Site, Essen, Germany

  • Novartis Investigative Site, Hamburg, Germany

  • Novartis Investigative Site, Hamburg, Germany

  • Novartis Investigative Site, Lüneburg, Germany

  • Novartis Investigative Site, Mannheim, Germany

  • Novartis Investigative Site, München, Germany

  • Novartis Investigative Site, Münster, Germany

  • Novartis Investigative Site, Oldenburg, Germany

  • Novartis Investigative Site, Beersheba, Israel

  • Novartis Investigative Site, Haifa, Israel

  • Novartis Investigative Site, Haifa, Israel

  • Novartis Investigative Site, Jerusalem, Israel

  • Novartis Investigative Site, Jerusalem, Israel

  • Novartis Investigative Site, Nahariya, Israel

  • Novartis Investigative Site, Petah Tikva, Israel

  • Novartis Investigative Site, Ramat Gan, Israel

  • Novartis Investigative Site, Tel Aviv, Israel

  • Novartis Investigative Site, Ancona, AN, Italy

  • Novartis Investigative Site, Bergamo, BG, Italy

  • Novartis Investigative Site, Bologna, BO, Italy

  • Novartis Investigative Site, Brescia, BS, Italy

  • Novartis Investigative Site, Caserta, CE, Italy

  • Novartis Investigative Site, Cona, FE, Italy

  • Novartis Investigative Site, Pozzilli, IS, Italy

  • Novartis Investigative Site, Milan, MI, Italy

  • Novartis Investigative Site, Milan, MI, Italy

  • Novartis Investigative Site, Milan, MI, Italy

  • Novartis Investigative Site, Padova, PD, Italy

  • Novartis Investigative Site, Pordenone, PN, Italy

  • Novartis Investigative Site, Amsterdam, North Holland, Netherlands

  • Novartis Investigative Site, Amsterdam, North Holland, Netherlands

  • Novartis Investigative Site, Rotterdam, South Holland, Netherlands

  • Novartis Investigative Site, Rotterdam, South Holland, Netherlands

  • Novartis Investigative Site, Nieuwegein, Utrecht, Netherlands

  • Novartis Investigative Site, Alcabideche, Portugal

  • Novartis Investigative Site, Braga, Portugal

  • Novartis Investigative Site, Coimbra, Portugal

  • Novartis Investigative Site, Vila Nova de Gaia, Portugal

  • Novartis Investigative Site, Cáceres, Extremadura, Spain

  • Novartis Investigative Site, Córdoba, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Salamanca, Spain

  • Novartis Investigative Site, Valencia, Spain

  • Novartis Investigative Site, Basel, Switzerland

  • Novartis Investigative Site, Geneva, Switzerland

  • Novartis Investigative Site, Lausanne, Switzerland

  • Novartis Investigative Site, Lugano, Switzerland

  • Novartis Investigative Site, Zurich, Switzerland

  • Novartis Investigative Site, Reading, Berkshire, United Kingdom

  • Novartis Investigative Site, Portadown, Nothern Ireland, United Kingdom

  • Novartis Investigative Site, Edinburgh, United Kingdom

  • Novartis Investigative Site, Leicester, United Kingdom

  • Novartis Investigative Site, Liverpool, United Kingdom

  • Novartis Investigative Site, London, United Kingdom

  • Novartis Investigative Site, London, United Kingdom

  • Novartis Investigative Site, Londonderry, United Kingdom

  • Novartis Investigative Site, Manchester, United Kingdom

  • Novartis Investigative Site, Middlesbrough, United Kingdom

  • Novartis Investigative Site, Norwich, United Kingdom

  • Novartis Investigative Site, Tyne and Wear, United Kingdom

Study leads

  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals

View source on ClinicalTrials.gov(opens in a new tab)Contact study team (email)